Janssen flags accelerated approval milestone in Europe for CAR-T therapy

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced they will perform an accelerated assessment of the Marketing Authorization Application (MAA) for Janssen’s investigational CAR-T therapy, ciltacabtagene autoleucel (cilta-cel).